Arsenic in the aetiology of cancer

Mutation Research - Reviews in Mutation Research

Volumn 612, Issue 3, 2006, Pages 215-246

  Tapio, Soile ^a   Grosche, Bernd ^a  

^a BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

Author keywords

Arsenic; Cancer; Drinking water; Mines; Molecular epidemiology

Indexed keywords

ARSENIC; GROUND WATER; RADON;

APOPTOSIS; ARSENIC POISONING; BIOTRANSFORMATION; BLADDER CANCER; CANCER; CARCINOGENESIS; CELL CYCLE REGULATION; CHROMOSOME ABERRATION; DNA METHYLATION; DNA REPAIR; GENE AMPLIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; METABOLIC REGULATION; MOLECULAR EPIDEMIOLOGY; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SKIN CANCER; SMOKING; WATER CONTAMINATION;

ARSENIC; BIOTRANSFORMATION; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY, MOLECULAR; HUMANS; NEOPLASMS; OCCUPATIONAL EXPOSURE;

EID: 33646776352     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrrev.2006.02.001     Document Type: Review

References (352)

1. Chen C.J., Chen C.W., Wu M.M., and Kuo T.L. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br. J. Cancer 66 (1992) 888-892
2. Chiou H.Y., Hsueh Y.M., Liaw K.F., Horng S.F., Chiang M.H., Pu Y.S., Lin J.S., Huang C.H., and Chen C.J. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 55 (1995) 1296-1300
3. Liu Y.T., and Chen Z. A retrospective lung cancer mortality study of people exposed to insoluble arsenic and radon. Lung Cancer 14 Suppl. 1 (1996) S137-S148
4. Chen C.J., and Wang C.J. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res. 50 (1990) 5470-5474
5. Tsai S.M., Wang T.N., and Ko Y.C. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch. Environ. Health 54 (1999) 186-193
6. IARC, Arsenic in Drinking-water, in: Some Drinking-water Disinfectants and Contaminants, Including Arsenic, vol. 84, IARC Press, Lyon, France, 2004, pp. 41-267.
7. Tseng C.H., Tseng C.P., Chiou H.Y., Hsueh Y.M., Chong C.K., and Chen C.J. Epidemiologic evidence of diabetogenic effect of arsenic. Toxicol. Lett. 133 (2002) 69-76
8. Chen C.J., Hsueh Y.M., Lai M.S., Shyu M.P., Chen S.Y., Wu M.M., Kuo T.L., and Tai T.Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25 (1995) 53-60
9. Tseng C.H., Chong C.K., Tseng C.P., Hsueh Y.M., Chiou H.Y., Tseng C.C., and Chen C.J. Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol. Lett. 137 (2003) 15-21
10. Chiou H.Y., Huang W.I., Su C.L., Chang S.F., Hsu Y.H., and Chen C.J. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 28 (1997) 1717-1723
11. Tomasek L., and Darby S.C. Recent results from the study of West Bohemian uranium miners exposed to radon and its progeny. Environ. Health Perspect. 103 Suppl. 2 (1995) 55-57
12. Chen W., and Chen J. Nested case-control study of lung cancer in four Chinese tin mines. Occup. Environ. Med. 59 (2002) 113-118
13. Qiao Y.L., Taylor P.R., Yao S.X., Erozan Y.S., Luo X.C., Barrett M.J., Yan Q.Y., Giffen C.A., Huang S.Q., Maher M.M., Forman M.R., and Tockman M.S. Risk factors and early detection of lung cancer in a cohort of Chinese tin miners. Ann. Epidemiol. 7 (1997) 533-541
14. Taylor P.R., Qiao Y.L., Schatzkin A., Yao S.X., Lubin J., Mao B.L., Rao J.Y., McAdams M., Xuan X.Z., and Li J.Y. Relation of arsenic exposure to lung cancer among tin miners in Yunnan Province, China. Br. J. Ind. Med. 46 (1989) 881-886
15. Kusiak R.A., Springer J., Ritchie A.C., and Muller J. Carcinoma of the lung in Ontario gold miners: possible aetiological factors. Br. J. Ind. Med. 48 (1991) 808-817
16. Simonato L., Moulin J.J., Javelaud B., Ferro G., Wild P., Winkelmann R., and Saracci R. A retrospective mortality study of workers exposed to arsenic in a gold mine and refinery in France. Am. J. Ind. Med. 25 (1994) 625-633
17. Viren J.R., and Silvers A. Unit risk estimates for airborne arsenic exposure: an updated view based on recent data from two copper smelter cohorts. Regul. Toxicol. Pharmacol. 20 (1994) 125-138
18. Lubin J.H., Pottern L.M., Stone B.J., and Fraumeni Jr. J.F. Respiratory cancer in a cohort of copper smelter workers: results from more than 50 years of follow-up. Am. J. Epidemiol. 151 (2000) 554-565
19. Liu J., Zheng B., Aposhian H.V., Zhou Y., Chen M.L., Zhang A., and Waalkes M.P. Chronic arsenic poisoning from burning high-arsenic-containing coal in Guizhou, China. Environ. Health Perspect. 110 (2002) 119-122
20. Rahman M., Wingren G., and Axelson O. Diabetes mellitus among Swedish art glass workers-an effect of arsenic exposure?. Scand. J. Work Environ. Health 22 (1996) 146-149
21. Abernathy C.O., Liu Y.P., Longfellow D., Aposhian H.V., Beck B., Fowler B., Goyer R., Menzer R., Rossman T., Thompson C., and Waalkes M. Arsenic: health effects, mechanisms of actions, and research issues. Environ. Health Perspect. 107 (1999) 593-597
22. Abernathy C.O., Thomas D.J., and Calderon R.L. Health effects and risk assessment of arsenic. J. Nutr. 133 (2003) 1536S-1538S
23. Miller Jr. W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 62 (2002) 3893-3903
24. Ferreccio C., Gonzalez C., Milosavjlevic V., Marshall G., Sancha A.M., and Smith A.H. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 11 (2000) 673-679
25. Hopenhayn-Rich C., Biggs M.L., and Smith A.H. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int. J. Epidemiol. 27 (1998) 561-569
26. Bates M.N., Smith A.H., and Cantor K.P. Case-control study of bladder cancer and arsenic in drinking water. Am. J. Epidemiol. 141 (1995) 523-530
27. Chen C.J., Wu M.M., Lee S.S., Wang J.D., Cheng S.H., and Wu H.Y. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 8 (1988) 452-460
28. Sun G. Arsenic contamination and arsenicosis in China. Toxicol. Appl. Pharmacol. 198 (2004) 268-271
29. Chowdhury U.K., Biswas B.K., Chowdhury T.R., Samanta G., Mandal B.K., Basu G.C., Chanda C.R., Lodh D., Saha K.C., Mukherjee S.K., Roy S., Kabir S., Quamruzzaman Q., and Chakraborti D. Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ. Health Perspect. 108 (2000) 393-397
30. Khan M.M., Sakauchi F., Sonoda T., Washio M., and Mori M. Magnitude of arsenic toxicity in tube-well drinking water in Bangladesh and its adverse effects on human health including cancer: evidence from a review of the literature. Asian Pac. J. Cancer Prev. 4 (2003) 7-14
31. WHO Guidelines for Drinking-water Quality (1998), WHO, Geneva
32. Karagas M.R., Stukel T.A., Morris J.S., Tosteson T.D., Weiss J.E., Spencer S.K., and Greenberg E.R. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am. J. Epidemiol. 153 (2001) 559-565
33. Calderon R.L., Hudgens E., Le X.C., Schreinemachers D., and Thomas D.J. Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ. Health Perspect. 107 (1999) 663-667
34. Yoshida T., Yamauchi H., and Fan G. Sun Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol. Appl. Pharmacol. 198 (2004) 243-252
35. Rossman T.G. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res. 533 (2003) 37-65
36. Styblo M., Del Razo L.M., Vega L., Germolec D.R., LeCluyse E.L., Hamilton G.A., Reed W., Wang C., Cullen W.R., and Thomas D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 74 (2000) 289-299
37. Del Razo L.M., Styblo M., Cullen W.R., and Thomas D.J. Determination of trivalent methylated arsenicals in biological matrices. Toxicol. Appl. Pharmacol. 174 (2001) 282-293
38. Mandal B.K., Ogra Y., Anzai K., and Suzuki K.T. Speciation of arsenic in biological samples. Toxicol. Appl. Pharmacol. 198 (2004) 307-318
39. Mohri T., Hisanaga A., and Ishinishi N. Arsenic intake and excretion by Japanese adults: a 7-day duplicate diet study. Food Chem. Toxicol. 28 (1990) 521-529
40. Smith A.H., Lingas E.O., and Rahman M. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull. World Health Organ. 78 (2000) 1093-1103
41. Wu M.M., Kuo T.L., Hwang Y.H., and Chen C.J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am. J. Epidemiol. 130 (1989) 1123-1132
42. Chen C.L., Hsu L.I., Chiou H.Y., Hsueh Y.M., Chen S.Y., Wu M.M., and Chen C.J. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA 292 (2004) 2984-2990
43. Tsuda T., Babazono A., Yamamoto E., Kurumatani N., Mino Y., Ogawa T., Kishi Y., and Aoyama H. Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. Am. J. Epidemiol. 141 (1995) 198-209
44. Kurttio P., Pukkala E., Kahelin H., Auvinen A., and Pekkanen J. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ. Health Perspect. 107 (1999) 705-710
45. Steinmaus C., Yuan Y., Bates M.N., and Smith A.H. Case-control study of bladder cancer and drinking water arsenic in the western United States. Am. J. Epidemiol. 158 (2003) 1193-1201
46. Bates M.N., Rey O.A., Biggs M.L., Hopenhayn C., Moore L.E., Kalman D., Steinmaus C., and Smith A.H. Case-control study of bladder cancer and exposure to arsenic in Argentina. Am. J. Epidemiol. 159 (2004) 381-389
47. Hertz-Picciotto I., and Smith A.H. Observations on the dose-response curve for arsenic exposure and lung cancer. Scand. J. Work Environ. Health 19 (1993) 217-226
48. Enterline P.E., Henderson V.L., and Marsh G.M. Exposure to arsenic and respiratory cancer. A reanalysis. Am. J. Epidemiol. 125 (1987) 929-938
49. Enterline P.E., Day R., and Marsh G.M. Cancers related to exposure to arsenic at a copper smelter. Occup. Environ. Med. 52 (1995) 28-32
50. Jarup L., and Pershagen G. Arsenic exposure, smoking, and lung cancer in smelter workers-a case-control study. Am. J. Epidemiol. 134 (1991) 545-551
51. Arrighi H.M., and Hertz-Picciotto I. Controlling the healthy worker survivor effect: an example of arsenic exposure and respiratory cancer. Occup. Environ. Med. 53 (1996) 455-462
52. Hertz-Picciotto I., Smith A.H., Holtzman D., Lipsett M., and Alexeeff G. Synergism between occupational arsenic exposure and smoking in the induction of lung cancer. Epidemiology 3 (1992) 23-31
53. Kadono T., Inaoka T., Murayama N., Ushijima K., Nagano M., Nakamura S., Watanabe C., Tamaki K., and Ohtsuka R. Skin manifestations of arsenicosis in two villages in Bangladesh. Int. J. Dermatol. 41 (2002) 841-846
54. Watanabe C., Inaoka T., Kadono T., Nagano M., Nakamura S., Ushijima K., Murayama N., Miyazaki K., and Ohtsuka R. Males in rural Bangladeshi communities are more susceptible to chronic arsenic poisoning than females: analyses based on urinary arsenic. Environ. Health Perspect. 109 (2001) 1265-1270
55. Guha Mazumder D.N., Haque R., Ghosh N., De B.K., Santra A., Chakraborty D., and Smith A.H. Arsenic levels in drinking water and the prevalence of skin lesions in West Bengal, India. Int. J. Epidemiol. 27 (1998) 871-877
56. Ohtsuka R., Sudo N., Sekiyama M., Watanabe C., Inaoka T., and Kadono T. Gender difference in daily time and space use among Bangladeshi villagers under arsenic hazard: application of the compact spot-check method. J. Biosoc. Sci. 36 (2004) 317-332
57. Kristiansen J., Christensen J.M., Iversen B.S., and Sabbioni E. Toxic trace element reference levels in blood and urine: influence of gender and lifestyle factors. Sci. Total Environ. 204 (1997) 147-160
58. Steenland K., and Thun M. Interaction between tobacco smoking and occupational exposures in the causation of lung cancer. J. Occup. Med. 28 (1986) 110-118
59. Hazelton W.D., Luebeck E.G., Heidenreich W.F., and Moolgavkar S.H. Analysis of a historical cohort of Chinese tin miners with arsenic, radon, cigarette smoke, and pipe smoke exposures using the biologically based two-stage clonal expansion model. Radiat. Res. 156 (2001) 78-94
60. Hsueh Y.M., Cheng G.S., Wu M.M., Yu H.S., Kuo T.L., and Chen C.J. Multiple risk factors associated with arsenic-induced skin cancer: effects of chronic liver disease and malnutritional status. Br. J. Cancer 71 (1995) 109-114
61. Mitra S.R., Mazumder D.N., Basu A., Block G., Haque R., Samanta S., Ghosh N., Smith M.M., von Ehrenstein O.S., and Smith A.H. Nutritional factors and susceptibility to arsenic-caused skin lesions in West Bengal, India. Environ. Health Perspect. 112 (2004) 1104-1109
62. Smith A.H., Arroyo A.P., Mazumder D.N., Kosnett M.J., Hernandez A.L., Beeris M., Smith M.M., and Moore L.E. Arsenic-induced skin lesions among Atacameno people in northern Chile despite good nutrition and centuries of exposure. Environ. Health Perspect. 108 (2000) 617-620
63. Hsueh Y.M., Ko Y.F., Huang Y.K., Chen H.W., Chiou H.Y., Huang Y.L., Yang M.H., and Chen C.J. Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicol. Lett. 137 (2003) 49-63
64. Spallholz J.E., Mallory Boylan L., and Rhaman M.M. Environmental hypothesis: is poor dietary selenium intake an underlying factor for arsenicosis and cancer in Bangladesh and West Bengal, India?. Sci. Total Environ. 323 (2004) 21-32
65. Rabbani G.H., Saha S.K., Akhtar M., Marni F., Mitra A.K., Ahmed S., Alauddin M., Bhattacharjee M., Sultana S., and Chowdhury A.K. Antioxidants in detoxification of arsenic-induced oxidative injury in rabbits: preliminary results. J. Environ. Sci. Health Part A: Tox. Hazard Subst. Environ. Eng. 38 (2003) 273-287
66. Ramanathan K., Shila S., Kumaran S., and Panneerselvam C. Protective role of ascorbic acid and alpha-tocopherol on arsenic-induced microsomal dysfunctions. Hum. Exp. Toxicol. 22 (2003) 129-136
67. Chattopadhyay S., Bhaumik S., Purkayastha M., Basu S., Nag Chaudhuri A., and Das Gupta S. Apoptosis and necrosis in developing brain cells due to arsenic toxicity and protection with antioxidants. Toxicol. Lett. 136 (2002) 65-76
68. Forman M.R., Yao S.X., Graubard B.I., Qiao Y.L., McAdams M., Mao B.L., and Taylor P.R. The effect of dietary intake of fruits and vegetables on the odds ratio of lung cancer among Yunnan tin miners. Int. J. Epidemiol. 21 (1992) 437-441
69. Ratnasinghe D., Forman M.R., Tangrea J.A., Qiao Y., Yao S.X., Gunter E.W., Barrett M.J., Giffen C.A., Erozan Y., Tockman M.S., and Taylor P.R. Serum carotenoids are associated with increased lung cancer risk among alcohol drinkers, but not among non-drinkers in a cohort of tin miners. Alcohol Alcohol. 35 (2000) 355-360
70. Hsueh Y.M., Chiou H.Y., Huang Y.L., Wu W.L., Huang C.C., Yang M.H., Lue L.C., Chen G.S., and Chen C.J. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 589-596
71. Ahsan H., Chen Y., Wang Q., Slavkovich V., Graziano J.H., and Santella R.M. DNA repair gene XPD and susceptibility to arsenic-induced hyperkeratosis. Toxicol. Lett. 143 (2003) 123-131
72. Ahsan H., Chen Y., Kibriya M.G., Islam M.N., Slavkovich V.N., Graziano J.H., and Santella R.M. Susceptibility to arsenic-induced hyperkeratosis and oxidative stress genes myeloperoxidase and catalase. Cancer Lett. 201 (2003) 57-65
73. Chiou H.Y., Hsueh Y.M., Hsieh L.L., Hsu L.I., Hsu Y.H., Hsieh F.I., Wei M.L., Chen H.C., Yang H.T., Leu L.C., Chu T.H., Chen-Wu C., Yang M.H., and Chen C.J. Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat. Res. 386 (1997) 197-207
74. Chung J.S., Kalman D.A., Moore L.E., Kosnett M.J., Arroyo A.P., Beeris M., Mazumder D.N., Hernandez A.L., and Smith A.H. Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ. Health Perspect. 110 (2002) 729-733
75. Bertolero F., Pozzi G., Sabbioni E., and Saffiotti U. Cellular uptake and metabolic reduction of pentavalent to trivalent arsenic as determinants of cytotoxicity and morphological transformation. Carcinogenesis 8 (1987) 803-808
76. Delnomdedieu M., Styblo M., and Thomas D.J. Time dependence of accumulation and binding of inorganic and organic arsenic species in rabbit erythrocytes. Chem. Biol. Interact. 98 (1995) 69-83
77. Vega L., Styblo M., Patterson R., Cullen W., Wang C., and Germolec D. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol. Appl. Pharmacol. 172 (2001) 225-232
78. Liu Z., Shen J., Carbrey J.M., Mukhopadhyay R., Agre P., and Rosen B.P. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 6053-6058
79. Huang R.N., and Lee T.C. Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Toxicol. Appl. Pharmacol. 136 (1996) 243-249
80. Kitchin K.T., and Wallace K. Arsenite binding to synthetic peptides based on the Zn finger region and the estrogen binding region of the human estrogen receptor-alpha. Toxicol. Appl. Pharmacol. 206 (2005) 66-72
81. Hughes M.F., and Kitchin K.T. In: K.K. S. (Ed). Arsenic, Oxidative Stress and Carcinogenesis Oxidative Stress, Disease and Cancer (2006), Imperial College Press, London
82. Marafante E., Vahter M., Norin H., Envall J., Sandstrom M., Christakopoulos A., and Ryhage R. Biotransformation of dimethylarsinic acid in mouse, hamster and man. J. Appl. Toxicol. 7 (1987) 111-117
83. Nemeti B., and Gregus Z. Mitochondria work as reactors in reducing arsenate to arsenite. Toxicol. Appl. Pharmacol. 182 (2002) 208-218
84. Aposhian H.V., Zakharyan R.A., Avram M.D., Kopplin M.J., and Wollenberg M.L. Oxidation and detoxification of trivalent arsenic species. Toxicol. Appl. Pharmacol. 193 (2003) 1-8
85. Parks D.A., and Granger D.N. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol. Scand. Suppl. 548 (1986) 87-99
86. 2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J. Biol. Chem. 270 (1995) 30334-30338
87. Hille R. The mononuclear molybdenum enzymes. Chem. Rev. 96 (1996) 2757-2816
88. 2 or ultraviolet B light. Arch. Dermatol. Res. 290 (1998) 113-118
89. Zakharyan R.A., and Aposhian H.V. Arsenite methylation by methylvitamin B12 and glutathione does not require an enzyme. Toxicol. Appl. Pharmacol. 154 (1999) 287-291
90. Styblo M., and Thomas D.J. Selenium modifies the metabolism and toxicity of arsenic in primary rat hepatocytes. Toxicol. Appl. Pharmacol. 172 (2001) 52-61
91. Walton F.S., Waters S.B., Jolley S.L., LeCluyse E.L., Thomas D.J., and Styblo M. Selenium compounds modulate the activity of recombinant rat AsIII-methyltransferase and the methylation of arsenite by rat and human hepatocytes. Chem. Res. Toxicol. 16 (2003) 261-265
92. Bailly R., Lauwerys R., Buchet J.P., Mahieu P., and Konings J. Experimental and human studies on antimony metabolism: their relevance for the biological monitoring of workers exposed to inorganic antimony. Br. J. Ind. Med. 48 (1991) 93-97
93. Buchet J.P., and Lauwerys R. Study of inorganic arsenic methylation by rat liver in vitro: relevance for the interpretation of observations in man. Arch. Toxicol. 57 (1985) 125-129
94. Gebel T. Arsenic and antimony: comparative approach on mechanistic toxicology. Chem. Biol. Interact. 107 (1997) 131-144
95. Gebel T. Suppression of arsenic-induced chromosome mutagenicity by antimony. Mutat. Res. 412 (1998) 213-218
96. Scott N., Hatlelid K.M., MacKenzie N.E., and Carter D.E. Reactions of arsenic(III) and arsenic(V) species with glutathione. Chem. Res. Toxicol. 6 (1993) 102-106
97. Cullen W.R., McBride B.C., and Reglinski J. The reaction of methylarsenicals with thiols: some biological implications. J. Inorg. Biochem. 21 (1984) 179-193
98. Delnomdedieu M., Basti M.M., Otvos J.D., and Thomas D.J. Transfer of arsenite from glutathione to dithiols: a model of interaction. Chem. Res. Toxicol. 6 (1993) 598-602
99. Kobayashi Y., Cui X., and Hirano S. Stability of arsenic metabolites, arsenic triglutathione [As(GS)(3)] and methylarsenic diglutathione [CH(3)As(GS)(2)], in rat bile. Toxicology 211 (2005) 115-123
100. Gregus Z., and Nemeti B. Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol. Sci. 70 (2002) 13-19
101. Nemeti B., and Gregus Z. Reduction of arsenate to arsenite in hepatic cytosol. Toxicol. Sci. 70 (2002) 4-12
102. Radabaugh T.R., Sampayo-Reyes A., Zakharyan R.A., and Aposhian H.V. Arsenate reductase. II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem. Res. Toxicol. 15 (2002) 692-698
103. Nemeti B., Csanaky I., and Gregus Z. Arsenate reduction in human erythrocytes and rats-testing the role of purine nucleoside phosphorylase. Toxicol. Sci. 74 (2003) 22-31
104. Zakharyan R.A., Sampayo-Reyes A., Healy S.M., Tsaprailis G., Board P.G., Liebler D.C., and Aposhian H.V. Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol. 14 (2001) 1051-1057
105. Zakharyan R.A., and Aposhian H.V. Enzymatic reduction of arsenic compounds in mammalian systems: the rate-limiting enzyme of rabbit liver arsenic biotransformation is MMA(V) reductase. Chem. Res. Toxicol. 12 (1999) 1278-1283
106. Tapio S., Danescu-Mayer J., Asmuss M., Posch A., Gomolka M., and Hornhardt S. Combined effects of gamma radiation and arsenite on the proteome of human TK6 lymphoblastoid cells. Mutat. Res. 581 (2005) 141-152
107. Zakharyan R., Wu Y., Bogdan G.M., and Aposhian H.V. Enzymatic methylation of arsenic compounds: assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem. Res. Toxicol. 8 (1995) 1029-1038
108. Lin S., Shi Q., Nix F.B., Styblo M., Beck M.A., Herbin-Davis K.M., Hall L.L., Simeonsson J.B., and Thomas D.J. A novel S-adenosyl-l-methionine:arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem. 277 (2002) 10795-10803
109. Thomas D.J., Waters S.B., and Styblo M. Elucidating the pathway for arsenic methylation. Toxicol. Appl. Pharmacol. 198 (2004) 319-326
110. Yoshida K., Inoue Y., Kuroda K., Chen H., Wanibuchi H., Fukushima S., and Endo G. Urinary excretion of arsenic metabolites after long-term oral administration of various arsenic compounds to rats. J. Toxicol. Environ. Health A 54 (1998) 179-192
111. Waters S.B., Devesa V., Fricke M.W., Creed J.T., Styblo M., and Thomas D.J. Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine. Chem. Res. Toxicol. 17 (2004) 1621-1629
112. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 181-182 (2002) 211-217
113. Gebel T.W. Arsenic methylation is a process of detoxification through accelerated excretion. Int. J. Hyg. Environ. Health 205 (2002) 505-508
114. Kligerman A.D., Doerr C.L., Tennant A.H., Harrington-Brock K., Allen J.W., Winkfield E., Poorman-Allen P., Kundu B., Funasaka K., Roop B.C., Mass M.J., and DeMarini D.M. Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ. Mol. Mutagen 42 (2003) 192-205
115. Thomas D.J., Styblo M., and Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 176 (2001) 127-144
116. Nesnow S., Roop B.C., Lambert G., Kadiiska M., Mason R.P., Cullen W.R., and Mass M.J. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem. Res. Toxicol. 15 (2002) 1627-1634
117. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., and Vasken Aposhian H. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163 (2000) 203-207
118. Petrick J.S., Jagadish B., Mash E.A., and Aposhian H.V. Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem. Res. Toxicol. 14 (2001) 651-656
119. Lin S., Del Razo L.M., Styblo M., Wang C., Cullen W.R., and Thomas D.J. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem. Res. Toxicol. 14 (2001) 305-311
120. Styblo M., Serves S.V., Cullen W.R., and Thomas D.J. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem. Res. Toxicol. 10 (1997) 27-33
121. Schwerdtle T., Walter I., and Hartwig A. Arsenite and its biomethylated metabolites interfere with the formation and repair of stable BPDE-induced DNA adducts in human cells and impair XPAzf and Fpg. DNA Repair (Amst.) 2 (2003) 1449-1463
122. Styblo M., and Thomas D.J. Binding of arsenicals to proteins in an in vitro methylation system. Toxicol. Appl. Pharmacol. 147 (1997) 1-8
123. Mass M.J., Tennant A., Roop B.C., Cullen W.R., Styblo M., Thomas D.J., and Kligerman A.D. Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol. 14 (2001) 355-361
124. Ahmad S., Kitchin K.T., and Cullen W.R. Plasmid DNA damage caused by methylated arsenicals, ascorbic acid and human liver ferritin. Toxicol. Lett. 133 (2002) 47-57
125. Dopp E., Hartmann L.M., Florea A.M., von Recklinghausen U., Pieper R., Shokouhi B., Rettenmeier A.W., Hirner A.V., and Obe G. Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. Toxicol. Appl. Pharmacol. 201 (2004) 156-165
126. Drobna Z., Jaspers I., Thomas D.J., and Styblo M. Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J. 17 (2003) 67-69
127. Sordo M., Herrera L.A., Ostrosky-Wegman P., and Rojas E. Cytotoxic and genotoxic effects of As, MMA, and DMA on leukocytes and stimulated human lymphocytes. Teratog. Carcinog. Mutagen. 21 (2001) 249-260
128. Yamanaka K., Takabayashi F., Mizoi M., An Y., Hasegawa A., and Okada S. Oral exposure of dimethylarsinic acid, a main metabolite of inorganic arsenics, in mice leads to an increase in 8-oxo-2′-deoxyguanosine level, specifically in the target organs for arsenic carcinogenesis. Biochem. Biophys. Res. Commun. 287 (2001) 66-70
129. Kato K., Hayashi H., Hasegawa A., Yamanaka K., and Okada S. DNA damage induced in cultured human alveolar (L-132) cells by exposure to dimethylarsinic acid. Environ. Health Perspect. 102 Suppl. 3 (1994) 285-288
130. Schwerdtle T., Walter I., Mackiw I., and Hartwig A. Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis 24 (2003) 967-974
131. Le X.C., Lu X., Ma M., Cullen W.R., Aposhian H.V., and Zheng B. Speciation of key arsenic metabolic intermediates in human urine. Anal. Chem. 72 (2000) 5172-5177
132. Mandal B.K., Ogra Y., and Suzuki K.T. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem. Res. Toxicol. 14 (2001) 371-378
133. Vahter M., and Concha G. Role of metabolism in arsenic toxicity. Pharmacol. Toxicol. 89 (2001) 1-5
134. Marnell L.L., Garcia-Vargas G.G., Chowdhury U.K., Zakharyan R.A., Walsh B., Avram M.D., Kopplin M.J., Cebrian M.E., Silbergeld E.K., and Aposhian H.V. Polymorphisms in the human monomethylarsonic acid (MMA(V)) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem. Res. Toxicol. 16 (2003) 1507-1513
135. Styblo M., Del Razo L.M., LeCluyse E.L., Hamilton G.A., Wang C., Cullen W.R., and Thomas D.J. Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem. Res. Toxicol. 12 (1999) 560-565
136. Drobna Z., Waters S.B., Walton F.S., LeCluyse E.L., Thomas D.J., and Styblo M. Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes. Toxicol. Appl. Pharmacol. 201 (2004) 166-177
137. Del Razo L.M., Garcia-Vargas G.G., Vargas H., Albores A., Gonsebatt M.E., Montero R., Ostrosky-Wegman P., Kelsh M., and Cebrian M.E. Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Arch. Toxicol. 71 (1997) 211-217
138. Concha G., Nermell B., and Vahter M.V. Metabolism of inorganic arsenic in children with chronic high arsenic exposure in northern Argentina. Environ. Health Perspect. 106 (1998) 355-359
139. Vahter M., Concha G., Nermell B., Nilsson R., Dulout F., and Natarajan A.T. A unique metabolism of inorganic arsenic in native Andean women. Eur. J. Pharmacol. 293 (1995) 455-462
140. Hopenhayn-Rich C., Biggs M.L., Smith A.H., Kalman D.A., and Moore L.E. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ. Health Perspect. 104 (1996) 620-628
141. Concha G., Vogler G., Lezcano D., Nermell B., and Vahter M. Exposure to inorganic arsenic metabolites during early human development. Toxicol. Sci. 44 (1998) 185-190
142. Kasprzak K.S. Oxidative DNA and protein damage in metal-induced toxicity and carcinogenesis. Free Radic. Biol. Med. 32 (2002) 958-967
143. Lloyd D.R., and Phillips D.H. Oxidative DNA damage mediated by copper(II), iron(II) and nickel(II) fenton reactions: evidence for site-specific mechanisms in the formation of double-strand breaks, 8-hydroxydeoxyguanosine and putative intrastrand cross-links. Mutat. Res. 424 (1999) 23-36
144. Harris G.K., and Shi X. Signaling by carcinogenic metals and metal-induced reactive oxygen species. Mutat. Res. 533 (2003) 183-200
145. Lee T.C., and Ho I.C. Modulation of cellular antioxidant defense activities by sodium arsenite in human fibroblasts. Arch. Toxicol. 69 (1995) 498-504
146. Lau A.T., He Q.Y., and Chiu J.F. A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosis. Biochem. J. Pt. (2004)
147. Applegate L.A., Luscher P., and Tyrrell R.M. Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res. 51 (1991) 974-978
148. Ryter S.W., and Choi A.M. Heme oxygenase-1: redox regulation of a stress protein in lung and cell culture models. Antioxid. Redox. Signal. 7 (2005) 80-91
149. Lee T.C., and Ho I.C. Differential cytotoxic effects of arsenic on human and animal cells. Environ. Health Perspect. 102 Suppl. 3 (1994) 101-105
150. Rea M.A., Gregg J.P., Qin Q., Phillips M.A., and Rice R.H. Global alteration of gene expression in human keratinocytes by inorganic arsenic. Carcinogenesis 24 (2003) 747-756
151. Zheng X.H., Watts G.S., Vaught S., and Gandolfi A.J. Low-level arsenite induced gene expression in HEK293 cells. Toxicology 187 (2003) 39-48
152. Brown J.L., Kitchin K.T., and George M. Dimethylarsinic acid treatment alters six different rat biochemical parameters: relevance to arsenic carcinogenesis. Teratog. Carcinog. Mutagen. 17 (1997) 71-84
153. Lee T.C., and Ho I.C. Expression of heme oxygenase in arsenic-resistant human lung adenocarcinoma cells. Cancer Res. 54 (1994) 1660-1664
154. Kenyon E.M., Del Razo L.M., Hughes M.F., and Kitchin K.T. An integrated pharmacokinetic and pharmacodynamic study of arsenite action. 2. Heme oxygenase induction in mice. Toxicology 206 (2005) 389-401
155. Kitchin K.T., Del Razo L.M., Brown J.L., Anderson W.L., and Kenyon E.M. An integrated pharmacokinetic and pharmacodynamic study of arsenite action. 1. Heme oxygenase induction in rats. Teratog. Carcinog. Mutagen. 19 (1999) 385-402
156. Yamanaka K., and Okada S. Induction of lung-specific DNA damage by metabolically methylated arsenics via the production of free radicals. Environ. Health Perspect. 102 Suppl. 3 (1994) 37-40
157. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172 (2001) 249-261
158. Liu S.X., Athar M., Lippai I., Waldren C., and Hei T.K. Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1643-1648
159. Smith K.R., Klei L.R., and Barchowsky A. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 280 (2001) L442-L449
160. Lynn S., Gurr J.R., Lai H.T., and Jan K.Y. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ. Res. 86 (2000) 514-519
161. Wei M., Wanibuchi H., Morimura K., Iwai S., Yoshida K., Endo G., Nakae D., and Fukushima S. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 23 (2002) 1387-1397
162. Vijayaraghavan M., Wanibuchi H., Karim R., Yamamoto S., Masuda C., Nakae D., Konishi Y., and Fukushima S. Dimethylarsinic acid induces 8-hydroxy-2′-deoxyguanosine formation in the kidney of NCI-Black-Reiter rats. Cancer Lett. 165 (2001) 11-17
163. Kessel M., Liu S.X., Xu A., Santella R., and Hei T.K. Arsenic induces oxidative DNA damage in mammalian cells. Mol. Cell. Biochem. 234-235 (2002) 301-308
164. Wei M., Arnold L., Cano M., and Cohen S.M. Effects of co-administration of antioxidants and arsenicals on the rat urinary bladder epithelium. Toxicol. Sci. 83 (2005) 237-245
165. Sen C.K. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem. Pharmacol. 55 (1998) 1747-1758
166. Wang T.S., Shu Y.F., Liu Y.C., Jan K.Y., and Huang H. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 121 (1997) 229-237
167. Yih L.H., and Lee T.C. Effects of exposure protocols on induction of kinetochore-plus and minus micronuclei by arsenite in diploid human fibroblasts. Mutat. Res. 440 (1999) 75-82
168. Wang T.S., Hsu T.Y., Chung C.H., Wang A.S., Bau D.T., and Jan K.Y. Arsenite induces oxidative DNA adducts and DNA-protein cross-links in mammalian cells. Free Radic. Biol. Med. 31 (2001) 321-330
169. Shimizu M., Hochadel J.F., Fulmer B.A., and Waalkes M.P. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Toxicol. Sci. 45 (1998) 204-211
170. Schuliga M., Chouchane S., and Snow E.T. Upregulation of glutathione-related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. Toxicol. Sci. 70 (2002) 183-192
171. Tapio S., Danescu-Mayer J., Asmuss M., Posch A., Gomolka M., and Hornhardt S. Combined effects of gamma radiation and arsenite on the proteome of human TK6 lymphoblastoid cells. Mut. Res. 581 (2005) 142-152
172. Matsui M., Nishigori C., Toyokuni S., Takada J., Akaboshi M., Ishikawa M., Imamura S., and Miyachi Y. The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2′-deoxyguanosine in arsenic-related Bowen's disease. J. Invest. Dermatol. 113 (1999) 26-31
173. Pi J., Yamauchi H., Kumagai Y., Sun G., Yoshida T., Aikawa H., Hopenhayn-Rich C., and Shimojo N. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ. Health Perspect. 110 (2002) 331-336
174. Qian Y., Castranova V., and Shi X. New perspectives in arsenic-induced cell signal transduction. J. Inorg. Biochem. 96 (2003) 271-278
175. Bode A.M., and Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 42 (2002) 5-24
176. Gozin A., Franzini E., Andrieu V., Da Costa L., Rollet-Labelle E., and Pasquier C. Reactive oxygen species activate focal adhesion kinase, paxillin and p130cas tyrosine phosphorylation in endothelial cells. Free Radic. Biol. Med. 25 (1998) 1021-1032
177. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
178. Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos. Trans. Roy. Soc. Lond. B: Biol. Sci. 353 (1998) 583-605
179. Kolibaba K.S., and Druker B.J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1333 (1997) F217-F248
180. Biscardi J.S., Tice D.A., and Parsons S.J. c-Src, receptor tyrosine kinases, and human cancer. Adv. Cancer Res. 76 (1999) 61-119
181. Franklin W.A., Veve R., Hirsch F.R., Helfrich B.A., and Bunn Jr. P.A. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin. Oncol. 29 (2002) 3-14
182. Kim E.S., Khuri F.R., and Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr. Opin. Oncol. 13 (2001) 506-513
183. Hossain K., Akhand A.A., Kato M., Du J., Takeda K., Wu J., Takeuchi K., Liu W., Suzuki H., and Nakashima I. Arsenite induces apoptosis of murine T lymphocytes through membrane raft-linked signaling for activation of c-Jun amino-terminal kinase. J. Immunol. 165 (2000) 4290-4297
184. Chen W., Martindale J.L., Holbrook N.J., and Liu Y. Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc. Mol. Cell. Biol. 18 (1998) 5178-5188
185. Wu W., Graves L.M., Jaspers I., Devlin R.B., Reed W., and Samet J.M. Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals. Am. J. Physiol. 277 (1999) L924-L931
186. Suc I., Meilhac O., Lajoie-Mazenc I., Vandaele J., Jurgens G., Salvayre R., and Negre-Salvayre A. Activation of EGF receptor by oxidized LDL. FASEB J. 12 (1998) 665-671
187. Boulton T.G., Nye S.H., Robbins D.J., Ip N.Y., Radziejewska E., Morgenbesser S.D., DePinho R.A., Panayotatos N., Cobb M.H., and Yancopoulos G.D. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65 (1991) 663-675
188. Kyriakis J.M., Banerjee P., Nikolakaki E., Dai T., Rubie E.A., Ahmad M.F., Avruch J., and Woodgett J.R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369 (1994) 156-160
189. Davis R.J. MAPKs: new JNK expands the group. Trends Biochem. Sci. 19 (1994) 470-473
190. Schaeffer H.J., and Weber M.J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 19 (1999) 2435-2444
191. Wu W., Jaspers I., Zhang W., Graves L.M., and Samet J.M. Role of Ras in metal-induced EGF receptor signaling and NF-kappaB activation in human airway epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 282 (2002) L1040-L1048
192. Barchowsky A., Roussel R.R., Klei L.R., James P.E., Ganju N., Smith K.R., and Dudek E.J. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol. Appl. Pharmacol. 159 (1999) 65-75
193. Simeonova P.P., Wang S., Hulderman T., and Luster M.I. c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. J. Biol. Chem. 277 (2002) 2945-2950
194. Simeonova P.P., and Luster M.I. Arsenic carcinogenicity: relevance of c-Src activation. Mol. Cell. Biochem. 234-235 (2002) 277-282
195. Angel P., and Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072 (1991) 129-157
196. Cavigelli M., Li W.W., Lin A., Su B., Yoshioka K., and Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. Embo J. 15 (1996) 6269-6279
197. Parrish A.R., Zheng X.H., Turney K.D., Younis H.S., and Gandolfi A.J. Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices. Toxicol. Sci. 50 (1999) 98-105
198. Simeonova P.P., Wang S., Toriuma W., Kommineni V., Matheson J., Unimye N., Kayama F., Harki D., Ding M., Vallyathan V., and Luster M.I. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res. 60 (2000) 3445-3453
199. Baeuerle P.A., and Henkel T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12 (1994) 141-179
200. Baldwin Jr. A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14 (1996) 649-683
201. Schulze-Osthoff K., Ferrari D., Riehemann K., and Wesselborg S. Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology 198 (1997) 35-49
202. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
203. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., and Baldwin Jr. A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19 (1999) 5785-5799
204. Gilmore T.D. Clinically relevant findings. J. Clin. Invest. 100 (1997) 2935-2936
205. Chen F., and Shi X. Signaling from toxic metals to NF-kappaB and beyond: not just a matter of reactive oxygen species. Environ. Health Perspect. 110 Suppl. 5 (2002) 807-811
206. Barchowsky A., Dudek E.J., Treadwell M.D., and Wetterhahn K.E. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic. Biol. Med. 21 (1996) 783-790
207. Roussel R.R., and Barchowsky A. Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch. Biochem. Biophys. 377 (2000) 204-212
208. Mahieux R., Pise-Masison C., Gessain A., Brady J.N., Olivier R., Perret E., Misteli T., and Nicot C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 98 (2001) 3762-3769
209. Kapahi P., Takahashi T., Natoli G., Adams S.R., Chen Y., Tsien R.Y., and Karin M. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J. Biol. Chem. 275 (2000) 36062-36066
210. Jaspers I., Samet J.M., and Reed W. Arsenite exposure of cultured airway epithelial cells activates kappaB-dependent interleukin-8 gene expression in the absence of nuclear factor-kappaB nuclear translocation. J. Biol. Chem. 274 (1999) 31025-31033
211. Li M., Cai J.F., and Chiu J.F. Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J. Cell. Biochem. 87 (2002) 29-38
212. Wijeweera J.B., Gandolfi A.J., Parrish A., and Lantz R.C. Sodium arsenite enhances AP-1 and NFkappaB DNA binding and induces stress protein expression in precision-cut rat lung slices. Toxicol. Sci. 61 (2001) 283-294
213. Chen Y.C., Lin-Shiau S.Y., and Lin J.K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J. Cell. Physiol. 177 (1998) 324-333
214. Wang T.S., Kuo C.F., Jan K.Y., and Huang H. Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J. Cell. Physiol. 169 (1996) 256-268
215. Ochi T., Nakajima F., Sakurai T., Kaise T., and Oya-Ohta Y. Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione. Arch. Toxicol. 70 (1996) 815-821
216. Woo S.H., Park I.C., Park M.J., Lee H.C., Lee S.J., Chun Y.J., Lee S.H., Hong S.I., and Rhee C.H. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int. J. Oncol. 21 (2002) 57-63
217. Guo J., and Zhang Z.Y. Investigation of apoptosis mechanism of arsenic trioxide on oral squamous cell carcinoma. Zhonghua Kou Qiang Yi Xue Za Zhi 38 (2003) 20-23
218. Chen F., Vallyathan V., Castranova V., and Shi X. Cell apoptosis induced by carcinogenic metals. Mol. Cell. Biochem. 222 (2001) 183-188
219. Hirata H., Takahashi A., Kobayashi S., Yonehara S., Sawai H., Okazaki T., Yamamoto K., and Sasada M. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med. 187 (1998) 587-600
220. Lee C.H., Yu C.L., Liao W.T., Kao Y.H., Chai C.Y., Chen G.S., and Yu H.S. Effects and interactions of low doses of arsenic and UVB on keratinocyte apoptosis. Chem. Res. Toxicol. 17 (2004) 1199-1205
221. Kang S.H., Song J.H., Kang H.K., Kang J.H., Kim S.J., Kang H.W., Lee Y.K., and Park D.B. Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells. Exp. Mol. Med. 35 (2003) 83-90
222. Nakagawa Y., Akao Y., Morikawa H., Hirata I., Katsu K., Naoe T., Ohishi N., and Yagi K. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci. 70 (2002) 2253-2269
223. Choi Y.J., Park J.W., Suh S.I., Mun K.C., Bae J.H., Song D.K., Kim S.P., and Kwon T.K. Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. Int. J. Oncol. 21 (2002) 603-610
224. Liao W.T., Chang K.L., Yu C.L., Chen G.S., Chang L.W., and Yu H.S. Arsenic induces human keratinocyte apoptosis by the FAS/FAS ligand pathway, which correlates with alterations in nuclear factor-kappa B and activator protein-1 activity. J. Invest. Dermatol. 122 (2004) 125-129
225. Komissarova E.V., Saha S.K., and Rossman T.G. Dead or dying: the importance of time in cytotoxicity assays using arsenite as an example. Toxicol. Appl. Pharmacol. 202 (2005) 99-107
226. Deng Y., Ren X., Yang L., Lin Y., and Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 115 (2003) 61-70
227. Chen G.Q., Zhu J., Shi X.G., Ni J.H., Zhong H.J., Si G.Y., Jin X.L., Tang W., Li X.S., Xong S.M., Shen Z.X., Sun G.L., Ma J., Zhang P., Zhang T.D., Gazin C., Naoe T., Chen S.J., Wang Z.Y., and Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88 (1996) 1052-1061
228. Huang C., Ma W.Y., Li J., and Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 59 (1999) 3053-3058
229. 3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int. J. Oncol. 21 (2002) 49-55
230. Jiang X.H., Wong B.C., Yuen S.T., Jiang S.H., Cho C.H., Lai K.C., Lin M.C., Kung H.F., and Lam S.K. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int. J. Cancer 91 (2001) 173-179
231. Hyun Park W., Hee Cho Y., Won Jung C., Oh Park J., Kim K., Hyuck Im Y., Lee M.H., Ki Kang W., and Park K. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem. Biophys. Res. Commun. 300 (2003) 230-235
232. Halicka H.D., Smolewski P., Darzynkiewicz Z., Dai W., and Traganos F. Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell Cycle 1 (2002) 201-209
233. Park J.W., Choi Y.J., Jang M.A., Baek S.H., Lim J.H., Passaniti T., and Kwon T.K. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem. Biophys. Res. Commun. 286 (2001) 726-734
234. Ling Y.H., Jiang J.D., Holland J.F., and Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol. Pharmacol. 62 (2002) 529-538
235. Alarcon-Vargas D., and Ronai Z. p53-Mdm2-the affair that never ends. Carcinogenesis 23 (2002) 541-547
236. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., and Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51 (1991) 6304-6311
237. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., and Reed J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9 (1994) 1799-1805
238. Tannoch V.J., Hinds P.W., and Tsai L.H. Cell cycle control. Adv. Exp. Med. Biol. 465 (2000) 127-140
239. Chen F., and Shi X. Intracellular signal transduction of cells in response to carcinogenic metals. Crit. Rev. Oncol. Hematol. 42 (2002) 105-121
240. Park W.H., Seol J.G., Kim E.S., Hyun J.M., Jung C.W., Lee C.C., Kim B.K., and Lee Y.Y. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 60 (2000) 3065-3071
241. Yih L.H., and Lee T.C. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res. 60 (2000) 6346-6352
242. Filippova M., and Duerksen-Hughes P.J. Inorganic and dimethylated arsenic species induce cellular p53. Chem. Res. Toxicol. 16 (2003) 423-431
243. Salazar A.M., Ostrosky-Wegman P., Menendez D., Miranda E., Garcia-Carranca A., and Rojas E. Induction of p53 protein expression by sodium arsenite. Mutat. Res. 381 (1997) 259-265
244. Vogt B.L., and Rossman T.G. Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts-a possible mechanism for arsenite's comutagenicity. Mutat. Res. 478 (2001) 159-168
245. Yager J.W., and Wiencke J.K. Inhibition of poly(ADP-ribose) polymerase by arsenite. Mutat. Res. 386 (1997) 345-351
246. Hu Y., Su L., and Snow E.T. Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat. Res. 408 (1998) 203-218
247. Rossman T.G., Uddin A.N., Burns F.J., and Bosland M.C. Arsenite cocarcinogenesis: an animal model derived from genetic toxicology studies. Environ. Health Perspect. 110 Suppl. 5 (2002) 749-752
248. Andrew A.S., Karagas M.R., and Hamilton J.W. Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int. J. Cancer 104 (2003) 263-268
249. Andrewes P., Kitchin K.T., and Wallace K. Dimethylarsine and trimethylarsine are potent genotoxins in vitro. Chem. Res. Toxicol. 16 (2003) 994-1003
250. Zhao C.Q., Young M.R., Diwan B.A., Coogan T.P., and Waalkes M.P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10907-10912
251. Mass M.J., and Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat. Res. 386 (1997) 263-277
252. Zhong C.X., and Mass M.J. Both hypomethylation and hypermethylation of DNA associated with arsenite exposure in cultures of human cells identified by methylation-sensitive arbitrarily-primed PCR. Toxicol. Lett. 122 (2001) 223-234
253. Chen H., Liu J., Merrick B.A., and Waalkes M.P. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol. Carcinog. 30 (2001) 79-87
254. Chen H., Liu J., Zhao C.Q., Diwan B.A., Merrick B.A., and Waalkes M.P. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol. Appl. Pharmacol. 175 (2001) 260-268
255. Chen H., Li S., Liu J., Diwan B.A., Barrett J.C., and Waalkes M.P. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 25 (2004) 1779-1786
256. Mure K., Uddin A.N., Lopez L.C., Styblo M., and Rossman T.G. Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations. Environ. Mol. Mutagen. 41 (2003) 322-331
257. Lee T.C., Tanaka N., Lamb P.W., Gilmer T.M., and Barrett J.C. Induction of gene amplification by arsenic. Science 241 (1988) 79-81
258. Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., and Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70 (1992) 923-935
259. Chou W.C., Hawkins A.L., Barrett J.F., Griffin C.A., and Dang C.V. Arsenic inhibition of telomerase transcription leads to genetic instability. J. Clin. Invest. 108 (2001) 1541-1547
260. Zhang T.C., Schmitt M.T., and Mumford J.L. Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis 24 (2003) 1811-1817
261. Shay J.W., and Gazdar A.F. Telomerase in the early detection of cancer. J. Clin. Pathol. 50 (1997) 106-109
262. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., and Greider C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91 (1997) 25-34
263. Hackett J.A., Feldser D.M., and Greider C.W. Telomere dysfunction increases mutation rate and genomic instability. Cell 106 (2001) 275-286
264. Barrett J.C., Lamb P.W., Wang T.C., and Lee T.C. Mechanisms of arsenic-induced cell transformation. Biol. Trace Elem. Res. 21 (1989) 421-429
265. Hei T.K., Liu S.X., and Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8103-8107
266. Vega L., Gonsebatt M.E., and Ostrosky-Wegman P. Aneugenic effect of sodium arsenite on human lymphocytes in vitro: an individual susceptibility effect detected. Mutat. Res. 334 (1995) 365-373
267. Basu A., Mahata J., Roy A.K., Sarkar J.N., Poddar G., Nandy A.K., Sarkar P.K., Dutta P.K., Banerjee A., Das M., Ray K., Roychaudhury S., Natarajan A.T., Nilsson R., and Giri A.K. Enhanced frequency of micronuclei in individuals exposed to arsenic through drinking water in West Bengal, India. Mutat. Res. 516 (2002) 29-40
268. Mahata J., Basu A., Ghoshal S., Sarkar J.N., Roy A.K., Poddar G., Nandy A.K., Banerjee A., Ray K., Natarajan A.T., Nilsson R., and Giri A.K. Chromosomal aberrations and sister chromatid exchanges in individuals exposed to arsenic through drinking water in West Bengal, India. Mutat. Res. 534 (2003) 133-143
269. Warner M.L., Moore L.E., Smith M.T., Kalman D.A., Fanning E., and Smith A.H. Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol. Biomarkers Prev. 3 (1994) 583-590
270. Schoen A., Beck B., Sharma R., and Dube E. Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicol. Appl. Pharmacol. 198 (2004) 253-267
271. Germolec D.R., Yoshida T., Gaido K., Wilmer J.L., Simeonova P.P., Kayama F., Burleson F., Dong W., Lange R.W., and Luster M.I. Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol. Appl. Pharmacol. 141 (1996) 308-318
272. Hamadeh H.K., Trouba K.J., Amin R.P., Afshari C.A., and Germolec D. Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol. Sci. 69 (2002) 306-316
273. Hu Y., Jin X., and Snow E.T. Effect of arsenic on transcription factor AP-1 and NF-kappaB DNA binding activity and related gene expression. Toxicol. Lett. 133 (2002) 33-45
274. Trouba K.J., Wauson E.M., and Vorce R.L. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol. Appl. Pharmacol. 164 (2000) 161-170
275. Goering P.L., Aposhian H.V., Mass M.J., Cebrian M., Beck B.D., and Waalkes M.P. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol. Sci. 49 (1999) 5-14
276. Yang J.L., Chen M.F., Wu C.W., and Lee T.C. Posttreatment with sodium arsenite alters the mutational spectrum induced by ultraviolet light irradiation in Chinese hamster ovary cells. Environ. Mol. Mutagen. 20 (1992) 156-164
277. Jha A.N., Noditi M., Nilsson R., and Natarajan A.T. Genotoxic effects of sodium arsenite on human cells. Mutat. Res. 284 (1992) 215-221
278. Li J.H., and Rossman T.G. Mechanism of comutagenesis of sodium arsenite with n-methyl-n-nitrosourea. Biol. Trace Elem. Res. 21 (1989) 373-381
279. Lee T.C., Lee K.C., Tzeng Y.J., Huang R.Y., and Jan K.Y. Sodium arsenite potentiates the clastogenicity and mutagenicity of DNA crosslinking agents. Environ. Mutagen. 8 (1986) 119-128
280. Cohen S.M., Arnold L.L., Uzvolgyi E., Cano M., St John M., Yamamoto S., Lu X., and Le X.C. Possible role of dimethylarsinous acid in dimethylarsinic acid-induced urothelial toxicity and regeneration in the rat. Chem. Res. Toxicol. 15 (2002) 1150-1157
281. Yamanaka K., Katsumata K., Ikuma K., Hasegawa A., Nakano M., and Okada S. The role of orally administered dimethylarsinic acid, a main metabolite of inorganic arsenics, in the promotion and progression of UVB-induced skin tumorigenesis in hairless mice. Cancer Lett. 152 (2000) 79-85
282. Yamanaka K., Ohtsubo K., Hasegawa A., Hayashi H., Ohji H., Kanisawa M., and Okada S. Exposure to dimethylarsinic acid, a main metabolite of inorganic arsenics, strongly promotes tumorigenesis initiated by 4-nitroquinoline 1-oxide in the lungs of mice. Carcinogenesis 17 (1996) 767-770
283. Yamamoto S., Konishi Y., Matsuda T., Murai T., Shibata M.A., Matsui-Yuasa I., Otani S., Kuroda K., Endo G., and Fukushima S. Cancer induction by an organic arsenic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens. Cancer Res. 55 (1995) 1271-1276
284. Wanibuchi H., Yamamoto S., Chen H., Yoshida K., Endo G., Hori T., and Fukushima S. Promoting effects of dimethylarsinic acid on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in rats. Carcinogenesis 17 (1996) 2435-2439
285. Wanibuchi H., Hori T., Meenakshi V., Ichihara T., Yamamoto S., Yano Y., Otani S., Nakae D., Konishi Y., and Fukushima S. Promotion of rat hepatocarcinogenesis by dimethylarsinic acid: association with elevated ornithine decarboxylase activity and formation of 8-hydroxydeoxyguanosine in the liver. Jpn. J. Cancer Res. 88 (1997) 1149-1154
286. Wei M., Wanibuchi H., Yamamoto S., Li W., and Fukushima S. Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. Carcinogenesis 20 (1999) 1873-1876
287. Styblo M., Drobna Z., Jaspers I., Lin S., and Thomas D.J. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 110 Suppl. 5 (2002) 767-771
288. Bau D.T., Wang T.S., Chung C.H., Wang A.S., and Jan K.Y. Oxidative DNA adducts and DNA-protein cross-links are the major DNA lesions induced by arsenite. Environ. Health Perspect. 110 Suppl. 5 (2002) 753-756
289. Hayashi H., Kanisawa M., Yamanaka K., Ito T., Udaka N., Ohji H., Okudela K., Okada S., and Kitamura H. Dimethylarsinic acid, a main metabolite of inorganic arsenics, has tumorigenicity and progression effects in the pulmonary tumors of A/J mice. Cancer Lett. 125 (1998) 83-88
290. Lee-Feldstein A. A comparison of several measures of exposure to arsenic. Matched case-control study of copper smelter employees. Am. J. Epidemiol. 129 (1989) 112-124
291. Kitchin K.T., and Ahmad S. Oxidative stress as a possible mode of action for arsenic carcinogenesis. Toxicol. Lett. 137 (2003) 3-13
292. Yamanaka K., Kato K., Mizoi M., An Y., Takabayashi F., Nakano M., Hoshino M., and Okada S. The role of active arsenic species produced by metabolic reduction of dimethylarsinic acid in genotoxicity and tumorigenesis. Toxicol. Appl. Pharmacol. 198 (2004) 385-393
293. Guo H.R., Wang N.S., Hu H., and Monson R.R. Cell type specificity of lung cancer associated with arsenic ingestion. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 638-643
294. Pershagen G., Wall S., Taube A., and Linnman L. On the interaction between occupational arsenic exposure and smoking and its relationship to lung cancer. Scand. J. Work Environ. Health 7 (1981) 302-309
295. Mazumdar S., Redmond C.K., Enterline P.E., Marsh G.M., Costantino J.P., Zhou S.Y., and Patwardhan R.N. Multistage modeling of lung cancer mortality among arsenic-exposed copper-smelter workers. Risk Anal. 9 (1989) 551-563
296. Jarup L., Pershagen G., and Wall S. Cumulative arsenic exposure and lung cancer in smelter workers: a dose-response study. Am. J. Ind. Med. 15 (1989) 31-41
297. Newman J.A., Archer V.E., Saccomanno G., Kuschner M., Auerbach O., Grondahl R.D., and Wilson J.C. Histologic types of bronchogenic carcinoma among members of copper-mining and smelting communities. Ann. N.Y. Acad. Sci. 271 (1976) 260-268
298. Axelson O., Dahlgren E., Jansson C.D., and Rehnlund S.O. Arsenic exposure and mortality: a case-referent study from a Swedish copper smelter. Br. J. Ind. Med. 35 (1978) 8-15
299. Wicks M.J., Archer V.E., Auerbach O., and Kuschner M. Arsenic exposure in a copper smelter as related to histological type of lung cancer. Am. J. Ind. Med. 2 (1981) 25-31
300. Pershagen G., Bergman F., Klominek J., Damber L., and Wall S. Histological types of lung cancer among smelter workers exposed to arsenic. Br. J. Ind. Med. 44 (1987) 454-458
301. Guo H.R., Yu H.S., Hu H., and Monson R.R. Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, ROC). Cancer Causes Contr. 12 (2001) 909-916
302. Castren K., Ranki A., Welsh J.A., and Vahakangas K.H. Infrequent p53 mutations in arsenic-related skin lesions. Oncol. Res. 10 (1998) 475-482
303. Hsu C.H., Yang S.A., Wang J.Y., Yu H.S., and Lin S.R. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br. J. Cancer 80 (1999) 1080-1086
304. Boonchai W., Walsh M., Cummings M., and Chenevix-Trench G. Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch. Dermatol. 136 (2000) 195-198
305. Rossman T.G., Uddin A.N., Burns F.J., and Bosland M.C. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol. Appl. Pharmacol. 176 (2001) 64-71
306. Yu R.C., Hsu K.H., Chen C.J., and Froines J.R. Arsenic methylation capacity and skin cancer. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 1259-1262
307. Pi J., Qu W., Reece J.M., Kumagai Y., and Waalkes M.P. Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide. Exp. Cell Res. 290 (2003) 234-245
308. Taeger D., and Pesch B. Arsenic in drinking water and bladder cancer mortality in the United States: an analysis based on 133 U.S. counties and 30 years of observation. J. Occup. Environ. Med. 46 (2004) 1007-1008 author reply 1009
309. Lamm S.H., Engel A., Kruse M.B., Feinleib M., Byrd D.M., Lai S., and Wilson R. Arsenic in drinking water and bladder cancer mortality in the United States: an analysis based on 133 U.S. counties and 30 years of observation. J. Occup. Environ. Med. 46 (2004) 298-306
310. Guo H.R., Chiang H.S., Hu H., Lipsitz S.R., and Monson R.R. Arsenic in drinking water and incidence of urinary cancers. Epidemiology 8 (1997) 545-550
311. Shibata A., Ohneseit P.F., Tsai Y.C., Spruck III C.H., Nichols P.W., Chiang H.S., Lai M.K., and Jones P.A. Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 15 (1994) 1085-1087
312. Moore L.E., Smith A.H., Eng C., DeVries S., Kalman D., Bhargava V., Chew K., Ferreccio C., Rey O.A., Hopenhayn C., Biggs M.L., Bates M.N., and Waldman F.M. P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis 24 (2003) 1785-1791
313. Moore L.E., Smith A.H., Eng C., Kalman D., DeVries S., Bhargava V., Chew K., Moore II D., Ferreccio C., Rey A.O., and Waldman F.M. Arsenic-related chromosomal alterations in bladder cancer. J. Natl. Cancer Inst. 94 (2002) 1688-1696
314. Hernandez-Zavala A., Cordova E., Del Razo L.M., Cebrian M.E., and Garrido E. Effects of arsenite on cell cycle progression in a human bladder cancer cell line. Toxicology 207 (2005) 49-57
315. Bredfeldt T.G., Kopplin M.J., and Gandolfi A.J. Effects of arsenite on UROtsa cells: low-level arsenite causes accumulation of ubiquitinated proteins that is enhanced by reduction in cellular glutathione levels. Toxicol. Appl. Pharmacol. 198 (2004) 412-418
316. L.S.R. Israel, Cacodylic acid: combined chronic feeding and oncogenity study in the rat, Study PAL010/CAC [MRID 418621-01, HED Documents 009391, 010550], 1989.
317. Luster M.I., and Simeonova P.P. Arsenic and urinary bladder cell proliferation. Toxicol. Appl. Pharmacol. 198 (2004) 419-423
318. Simeonova P.P., Wang S., Kashon M.L., Kommineni C., Crecelius E., and Luster M.I. Quantitative relationship between arsenic exposure and AP-1 activity in mouse urinary bladder epithelium. Toxicol. Sci. 60 (2001) 279-284
319. Wanibuchi H., Salim E.I., Kinoshita A., Shen J., Wei M., Morimura K., Yoshida K., Kuroda K., Endo G., and Fukushima S. Understanding arsenic carcinogenicity by the use of animal models. Toxicol. Appl. Pharmacol. 198 (2004) 366-376
320. Luchtrath H. The consequences of chronic arsenic poisoning among Moselle wine growers. Pathoanatomical investigations of post-mortem examinations performed between 1960 and 1977. J. Cancer Res. Clin. Oncol. 105 (1983) 173-182
321. Kasper M.L., Schoenfield L., Strom R.L., and Theologides A. Hepatic angiosarcoma and bronchioloalveolar carcinoma induced by Fowler's solution. JAMA 252 (1984) 3407-3408
322. Chiu H.F., Ho S.C., Wang L.Y., Wu T.N., and Yang C.Y. Does arsenic exposure increase the risk for liver cancer?. J. Toxicol. Environ. Health A 67 (2004) 1491-1500
323. Santra A., Das Gupta J., De B.K., Roy B., and Guha Mazumder D.N. Hepatic manifestations in chronic arsenic toxicity. Indian J. Gastroenterol. 18 (1999) 152-155
324. Santra A., Maiti A., Chowdhury A., and Mazumder D.N. Oxidative stress in liver of mice exposed to arsenic-contaminated water. Indian J. Gastroenterol. 19 (2000) 112-115
325. Guha Mazumder D.N. Arsenic and liver disease. J. Indian Med. Assoc. 99 (2001) 311, 314, 315, 318-320
326. Wang Z., Hou G., and Rossman T.G. Induction of arsenite tolerance and thermotolerance by arsenite occur by different mechanisms. Environ. Health Perspect. 102 Suppl. 3 (1994) 97-100
327. Qu W., Kasprzak K.S., Kadiiska M., Liu J., Chen H., Maciag A., Mason R.P., and Waalkes M.P. Mechanisms of arsenic-induced cross-tolerance to nickel cytotoxicity, genotoxicity, and apoptosis in rat liver epithelial cells. Toxicol. Sci. 63 (2001) 189-195
328. Lappas G.D., Karl I.E., and Hotchkiss R.S. Effect of ethanol and sodium arsenite on HSP-72 formation and on survival in a murine endotoxin model. Shock 2 (1994) 34-39 discussion 40
329. Vahter M. Metabolism of Arsenic (1983), Elsevier, Amsterdam
330. Romach E.H., Zhao C.Q., Del Razo L.M., Cebrian M.E., and Waalkes M.P. Studies on the mechanisms of arsenic-induced self-tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol. Sci. 54 (2000) 500-508
331. Huang H., Huang C.F., Wu D.R., Jinn C.M., and Jan K.Y. Glutathione as a cellular defence against arsenite toxicity in cultured Chinese hamster ovary cells. Toxicology 79 (1993) 195-204
332. Brambila E.M., Achanzar W.E., Qu W., Webber M.M., and Waalkes M.P. Chronic arsenic-exposed human prostate epithelial cells exhibit stable arsenic tolerance: mechanistic implications of altered cellular glutathione and glutathione S-transferase. Toxicol. Appl. Pharmacol. 183 (2002) 99-107
333. Barnes J.A., Collins B.W., Dix D.J., and Allen J.W. Effects of heat shock protein 70 (Hsp70) on arsenite-induced genotoxicity. Environ. Mol. Mutagen. 40 (2002) 236-242
334. Del Razo L.M., Quintanilla-Vega B., Brambila-Colombres E., Calderon-Aranda E.S., Manno M., and Albores A. Stress proteins induced by arsenic. Toxicol. Appl. Pharmacol. 177 (2001) 132-148
335. Lau A.T., Li M., Xie R., He Q.Y., and Chiu J.F. Opposed arsenite-induced signaling pathways promote cell proliferation or apoptosis in cultured lung cells. Carcinogenesis 25 (2004) 21-28
336. R. Wilson, http://phys4.harvard.edu/∼wilson/arsenic/arsenic_project_introduction.html, 2005.
337. EASHW, http://europe.osha.eu.int/good_practice/risks/ds/oel/, European Agency for Safety and Health at Work, 2005.
338. Smith A.H., and Smith M.M. Arsenic drinking water regulations in developing countries with extensive exposure. Toxicology 198 (2004) 39-44
339. Brown K.G., and Ross G.L. Arsenic, drinking water, and health: a position paper of the American Council on Science and Health. Regul. Toxicol. Pharmacol. 36 (2002) 162-174
340. HSE, EH 40 Occupational Exposure Limits 2002, HSE, 2002.
341. The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) (1996), ACGIH, Cincinnati, OH
342. In: Schlecht P.C., and O'Connor P.F. (Eds). Manual of Analytical Methods (1994), NIOSH
343. MacDonald R. Providing clean water: lessons from Bangladesh. BMJ 322 (2001) 626-627
344. Mandal B.K., and Suzuki K.T. Arsenic round the world: a review. Talanta 58 (2002) 201-235
345. Rahman M.M., Mandal B.K., Chowdhury T.R., Sengupta M.K., Chowdhury U.K., Lodh D., Chanda C.R., Basu G.K., Mukherjee S.C., Saha K.C., and Chakraborti D. Arsenic groundwater contamination and sufferings of people in North 24-Parganas, one of the nine arsenic affected districts of West Bengal, India. J. Environ. Sci. Health A: Tox. Hazard. Subst. Environ. Eng. 38 (2003) 25-59
346. Xia Y., and Liu J. An overview on chronic arsenism via drinking water in PR China. Toxicology 198 (2004) 25-29
347. Liu C.W., Jang C.S., and Liao C.M. Evaluation of arsenic contamination potential using indicator kriging in the Yun-Lin aquifer (Taiwan). Sci. Total Environ. 321 (2004) 173-188
348. C.Y. Yang, personal communication.
349. Berg M., Tran H.C., Nguyen T.C., Pham H.V., Schertenleib R., and Giger W. Arsenic contamination of groundwater and drinking water in Vietnam: a human health threat. Environ. Sci. Technol. 35 (2001) 2621-2626
350. Del Razo L.M., Arellano M.A., and Cebrian M.E. The oxidation states of arsenic in well-water from a chronic arsenicism area of northern Mexico. Environ. Pollut. 64 (1990) 143-153
351. Hopenhayn C., Ferreccio C., Browning S.R., Huang B., Peralta C., Gibb H., and Hertz-Picciotto I. Arsenic exposure from drinking water and birth weight. Epidemiology 14 (2003) 593-602
352. Kurttio P., Komulainen H., Hakala E., Kahelin H., and Pekkanen J. Urinary excretion of arsenic species after exposure to arsenic present in drinking water. Arch. Environ. Contam. Toxicol. 34 (1998) 297-305